23 results on '"Ignatius, Elisa H"'
Search Results
2. Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease
- Author
-
Strnad, Luke, Varley, Cara, Lapidus, Jodi, Philley, Julie, McShane, Pamela, Devine, Megan, Griffith, David E., Kasperbauer, Shannon H., Huitt, Gwen, Eddy, Jared J., Marras, Theodore K., Brode, Sarah K., Addrizzo-Harris, Dorreen, Springer, Amy, Flume, Patrick, Mingora, Christina, Alkabab, Yursa, Dorman, Susan, Naureckas, Ted, Aksamit, Timothy R., Ruoss, Stephen, Hornick, Douglas B., Mirsaeidi, Mehdi, Salathe, Matthias, Waller, Stephen, Schmid, Andreas, ElMaraachli, Wael, Cowell, Anne, Thakur, Neeta, Nahid, Payam, Zha, Shoshana, Ignatius, Elisa H., Zenilman, Jonathan, Cohen, Keira, Belz, Daniel C., Ali, Juzar, Lapinel, Nicole, Swenson, Colin, Kapolka, Rebecca, Horne, David, Salerno, Daniel, DiMango, Angela, Moretta, Dafne, Tan, Laren, Furukawa, Brian, Wysham, Nicholas, Noone, Peader, Daniels, Leigh Anne, Chris Saddler, Misch, Elizabeth Ann, Hayes, Lisa, Epstein, Marcia, Kim, Angela, Myers, Janet N., Henkle, Emily, Quittner, Alexandra L., Dieckmann, Nathan F., Franklin, Heather, Brunton, Amanda E., Daley, Charles L., and Winthrop, Kevin L.
- Published
- 2023
- Full Text
- View/download PDF
3. High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.
- Author
-
Gausi, Kamunkhwala, Ignatius, Elisa H., De Jager, Veronique, Upton, Caryn, Kim, Soyeon, McKhann, Ashley, Moran, Laura, Wiesner, Lubbe, von Groote-Bidlingmaier, Florian, Marzinek, Philip, Vanker, Naadira, Yvetot, Joseph, Pierre, Samuel, Rosenkranz, Susan L., Swindells, Susan, Diacon, Andreas H., Nuermberger, Eric L., Denti, Paolo, and Dooley, Kelly E.
- Subjects
ISONIAZID ,MULTIDRUG-resistant tuberculosis ,TUBERCULOSIS ,CLINICAL trials ,BACTERICIDAL action ,MYCOBACTERIUM tuberculosis - Abstract
Rationale: Observational studies suggest that high-dose isoniazid may be efficacious in treating multidrug-resistant tuberculosis. However, its activity against Mycobacterium tuberculosis (M.tb) with katG mutations (which typically confer high-level resistance) is not established. Objectives: To characterize the early bactericidal activity (EBA) of high-dose isoniazid in patients with tuberculosis caused by katG-mutated M.tb. Methods: A5312 was a phase IIA randomized, open-label trial. Participants with tuberculosis caused by katG-mutated M.tb were randomized to receive 15 or 20 mg/kg isoniazid daily for 7 days. Daily sputum samples were collected for quantitative culture. Intensive pharmacokinetic sampling was performed on Day 6. Data were pooled across all A5312 participants for analysis (drug-sensitive, inhA-mutated, and katG-mutated M.tb). EBA was determined using nonlinear mixed-effects modeling. Measurements and Main Results: Of 80 treated participants, 21 had katG-mutated M.tb. Isoniazid pharmacokinetics were best described by a two-compartment model with an effect of NAT2 acetylator phenotype on clearance. Model-derived maximum concentration and area under the concentration–time curve in the 15 and 20 mg/kg groups were 15.0 and 22.1 mg/L and 57.6 and 76.8 mg ⋅ h/L, respectively. Isoniazid bacterial kill was described using an effect compartment and a sigmoidal maximum efficacy relationship. Isoniazid potency against katG-mutated M.tb was approximately 10-fold lower than in inhA-mutated M.tb. The highest dose of 20 mg/kg did not demonstrate measurable EBA, except against a subset of slow NAT2 acetylators (who experienced the highest concentrations). There were no grade 3 or higher drug-related adverse events. Conclusions: This study found negligible bactericidal activity of high-dose isoniazid (15–20 mg/kg) in the majority of participants with tuberculosis caused by katG-mutated M.tb. Clinical trial registered with (NCT01936831). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients
- Author
-
Malo, Andisiwe, Kellermann, Tracy, Ignatius, Elisa H., Dooley, Kelly E., Dawson, Rodney, Joubert, Anton, Norman, Jennifer, Castel, Sandra, and Wiesner, Lubbe
- Published
- 2021
- Full Text
- View/download PDF
5. Efficacies of omadacycline + amikacin + imipenem and an alloral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease.
- Author
-
Ignatius, Elisa H., Rimal, Binayak, Panthi, Chandra M., Belz, Daniel C., Lippincott, Christopher K., Deck, Daniel H., Serio, Alisa W., and Lamichhane, Gyanu
- Published
- 2024
- Full Text
- View/download PDF
6. Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB
- Author
-
Ignatius, Elisa H. and Swindells, Susan
- Published
- 2020
- Full Text
- View/download PDF
7. Getting to the point in point-of-care diagnostics for tuberculosis
- Author
-
Ignatius, Elisa H., Cohen, Keira A., and Bishai, William R.
- Subjects
Medical tests -- Methods ,Pulmonary tuberculosis -- Diagnosis ,Health care industry - Abstract
Tuberculosis (TB) continues to affect over 10 million people per year worldwide. Despite advances in diagnosis, smear microscopy insufficiently detects pulmonary disease, with test result reporting taking longer than a day. While urine assays to detect the lipopolysaccharide lipoarabinomannan (LAM), present in mycobacterial cell walls, can provide results within minutes, the currently available assay has low sensitivity and its application is limited to patients with HIV suspected of having TB. In this issue of the JCI, Broger and Nicol et al. investigated 3 rapid urine tests in 372 ambulatory HIV-negative individuals suspected of having TB in South Africa and Peru. FujiLAM emerged as a rapid test to confirm TB diagnosis in the HIVseronegative population. This study shows that FujiLAM has considerable potential to reshape the TB diagnostics landscape, making diagnosis and treatment in one office visit a reality for TB., Rapid tests for pulmonary TB Despite the World Health Organization's (WHO) designation of tuberculosis (TB) as a global health emergency nearly 30 years ago, a true point-of-care diagnostic test for [...]
- Published
- 2020
- Full Text
- View/download PDF
8. Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.
- Author
-
Rimal, Binayak, Nicklas, Danielle A., Panthi, Chandra M., Lippincott, Christopher K., Belz, Daniel C., Ignatius, Elisa H., Deck, Daniel H., Serio, Alisa W., and Lamichhane, Gyanu
- Published
- 2023
- Full Text
- View/download PDF
9. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.
- Author
-
Dooley, Kelly E., Hendricks, Bronwyn, Gupte, Nikhil, Barnes, Grace, Narunsky, Kim, Whitelaw, Colleen, Smit, Tanya, Ignatius, Elisa H., Friedman, Adine, Dorman, Susan E., and Dawson, Rodney
- Subjects
TUBERCULOSIS ,ISONIAZID - Abstract
Rationale: Pretomanid is a new nitroimidazole with proven treatment-shortening efficacy in drug-resistant tuberculosis. Pretomanid-rifamycin-pyrazinamide combinations are potent in mice but have not been tested clinically. Rifampicin, but not rifabutin, reduces pretomanid exposures.Objective: Evaluate the safety and efficacy of pretomanid-rifamycin-pyrazinamide containing regimens among participants with drug-sensitive pulmonary tuberculosis.Methods: Phase 2 twelve-week open-label randomized trial of isoniazid, pyrazinamide, plus (a) pretomanid and rifampicin (Arm 1); (b) pretomanid and rifabutin (Arm 2) or (c) rifampicin and ethambutol (standard of care, Arm 3). Safety labs and sputum cultures were collected at Weeks 1, 2, 3, 4, 6, 8, 10, 12. Time to culture conversion on liquid media was the primary outcome.Results: Among 157 participants, 125 (80%) had cavitary disease. Median time to liquid culture negativity in the modified intention to treat (mITT) population (n=150) was 41 (Arm 1), 28 (Arm 2), and 55 (Arm 3) days (p=0.01)(adjusted hazard ratios of 1.41 (0.93-2.12, p=0.10), Arm 1 vs. Arm 3) and 1.89 (1.24-2.87, p=0.003, Arm 2 vs. Arm 3)). Eight-week liquid culture conversion was 79%, 89%, and 69%, respectively. Grade >3 adverse events occurred in 3/56 (5%), 5/53 (9%), and 2/56 (4%) of participants. Six participants were withdrawn owing to elevated transaminases (5 in Arm 2, 1 in Arm 1).There were 3 serious adverse events (Arm 2) and no deaths.Conclusions: Pretomanid enhanced the microbiologic activity of rifamycin-pyrazinamide containing regimens. Efficacy and hepatic adverse events appeared highest with the pretomanid and rifabutin-containing regimen. Whether this is due to higher pretomanid concentrations merits exploration. Clinical trial registration available at www.Clinicaltrials: gov, ID: NCT02256696. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
10. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
- Author
-
Gausi, Kamunkhwala, Chirehwa, Maxwell, Ignatius, Elisa H, Court, Richard, Sun, Xin, Moran, Laura, Hafner, Richard, Wiesner, Lubbe, Rosenkranz, Susan L, Jager, Veronique de, Vries, Nihal de, Harding, Joseph, Gumbo, Tawanda, Swindells, Susan, Diacon, Andreas, Dooley, Kelly E, McIlleron, Helen, Denti, Paolo, de Jager, Veronique, and de Vries, Nihal
- Abstract
Background: The WHO-endorsed shorter-course regimen for MDR-TB includes high-dose isoniazid. The pharmacokinetics of high-dose isoniazid within MDR-TB regimens has not been well described.Objectives: To characterize isoniazid pharmacokinetics at 5-15 mg/kg as monotherapy or as part of the MDR-TB treatment regimen.Methods: We used non-linear mixed-effects modelling to evaluate the combined data from INHindsight, a 7 day early bactericidal activity study with isoniazid monotherapy, and PODRtb, an observational study of patients on MDR-TB treatment including terizidone, pyrazinamide, moxifloxacin, kanamycin, ethionamide and/or isoniazid.Results: A total of 58 and 103 participants from the INHindsight and PODRtb studies, respectively, were included in the analysis. A two-compartment model with hepatic elimination best described the data. N-acetyltransferase 2 (NAT2) genotype caused multi-modal clearance, and saturable first-pass was observed beyond 10 mg/kg dosing. Saturable isoniazid kinetics predicted an increased exposure of approximately 50% beyond linearity at 20 mg/kg dosing. Participants treated with the MDR-TB regimen had a 65.6% lower AUC compared with participants on monotherapy. Ethionamide co-administration was associated with a 29% increase in isoniazid AUC.Conclusions: Markedly lower isoniazid exposures were observed in participants on combination MDR-TB treatment compared with monotherapy. Isoniazid displays saturable kinetics at doses >10 mg/kg. The safety implications of these phenomena remain unclear. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease.
- Author
-
Dedrick, Rebekah M, Freeman, Krista G, Nguyen, Jan A, Bahadirli-Talbott, Asli, Cardin, Mitchell E, Cristinziano, Madison, Smith, Bailey E, Jeong, Soowan, Ignatius, Elisa H, Lin, Cheng Ting, Cohen, Keira A, and Hatfull, Graham F
- Subjects
MYCOBACTERIUM ,LUNG diseases ,BACTERIOPHAGES ,OLDER men ,INTRAVENOUS therapy ,BURULI ulcer - Abstract
An elderly man with refractory Mycobacterium abscessus lung disease previously developed anti-phage neutralizing antibodies while receiving intravenous phage therapy. Subsequent phage nebulization resulted in transient weight gain, decreased C-reactive protein, and reduced Mycobacterium burden. Weak sputum neutralization may have limited the outcomes, but phage resistance was not a contributing factor. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Update on Tuberculosis/HIV Coinfections: Across the Spectrum From Latent Infection Through Drug-Susceptible and Drug-Resistant Disease.
- Author
-
Ignatius, Elisa H. and Swindells, Susan
- Published
- 2022
13. A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial.
- Author
-
Gausi, Kamunkhwala, Ignatius, Elisa H., Xin Sun, Soyeon Kim, Moran, Laura, Wiesner, Lubbe, von Groote-Bidlingmaier, Florian, Hafner, Richard, Donahue, Kathleen, Vanker, Naadira, Rosenkranz, Susan L., Swindells, Susan, Diacon, Andreas H., Nuermberger, Eric L., Dooley, Kelly E., Denti, Paolo, Sun, Xin, and Kim, Soyeon
- Subjects
ISONIAZID ,MYCOBACTERIUM tuberculosis ,PHARMACOKINETICS ,TUBERCULOSIS ,BACTERICIDAL action ,TUBERCULOSIS microbiology ,SPUTUM microbiology ,DRUG therapy for tuberculosis ,BACTERIAL proteins ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RANDOMIZED controlled trials ,ANTITUBERCULAR agents ,TRANSFERASES ,DOSE-effect relationship in pharmacology ,BACTERIAL growth ,MICROBIOLOGICAL techniques ,RESEARCH funding ,OXIDOREDUCTASES ,MICROBIAL sensitivity tests - Abstract
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but the optimal dose remains unknown. Objectives: To characterize the association between isoniazid pharmacokinetics (standard or high dose) and early bactericidal activity against M. tuberculosis (drug sensitive and inhA mutated) and N-acetyltransferase 2 status. Methods: ACTG (AIDS Clinical Trial Group) A5312/INHindsight is a 7-day early bactericidal activity study with isoniazid at a normal dose (5 mg/kg) for patients with drug-sensitive bacteria and 5, 10, and 15 mg/kg doses for patients with inhA mutants. Participants with pulmonary tuberculosis received daily isoniazid monotherapy and collected sputum daily. Colony-forming units (cfu) on solid culture and time to positivity in liquid culture were jointly analyzed using nonlinear mixed-effects modeling. Measurements and Main Results: Fifty-nine adults were included in this analysis. A decline in sputum cfu was described by a one-compartment model, whereas an exponential bacterial growth model was used to interpret time-to-positivity data. The model found that bacterial kill is modulated by isoniazid concentration using an effect compartment and a sigmoidal Emax relationship (a model linking the drug concentration to the observed effect). The model predicted lower potency but similar maximum kill of isoniazid against inhA-mutated compared with drug-sensitive isolates. Based on simulations from the pharmacokinetics-pharmacodynamics model, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, 10- and 15-mg/kg doses are necessary against inhA-mutated isolates in slow and intermediate N-acetyltransferase 2 acetylators, respectively. Fast acetylators underperformed even at 15 mg/kg. Conclusions: Dosing of isoniazid based on N-acetyltransferase 2 acetylator status may help patients attain effective exposures against inhA-mutated isolates. Clinical trial registered with www.clinicaltrials.gov (NCT01936831). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia.
- Author
-
Xavier Hall, Casey D., Smith, Justin C., Driggers, Robert A., Stoller, Bethany, Khan, Zara, Li, Jingjing, Ignatius, Elisa H., and Siegler, Aaron J.
- Subjects
PREVENTION of infectious disease transmission ,HIV infections ,ATTITUDE (Psychology) ,MEDICAL personnel ,INTERVIEWING ,QUALITATIVE research ,PREVENTIVE medicine ,THEMATIC analysis - Abstract
New modalities of Pre-exposure Prophylaxis (PrEP) such as long-acting injectable PrEP (LAI-PrEP) promise increased prevention of HIV transmission; however, similar biomedical interventions have not been met with universal adoption by healthcare providers or populations most affected by HIV. This qualitative study explores healthcare provider considerations for the rollout of LAI-PrEP. Eleven key-informant in-depth interviews were conducted with clinicians who prescribe daily oral PrEP. Participants reviewed a currently proposed LAI regimen and were asked to reflect on its implications for their clinical practice. Interviews were transcribed verbatim and thematically coded, with results organized using the Consolidated Framework for Implementation Research (CFIR). All participants expressed interest in prescribing LAI-PrEP and anticipated that at least some patients would be interested. Participants identified characteristics of the intervention, inner intervention setting, and outer intervention setting that will be influential in bringing LAI-PrEP to scale. Clinicians in the South have unique insights into the challenges of and opportunities for successful rollout of future PrEP regimens. Bringing these insights into a CFIR framework highlights the nuances surrounding LAI-PrEP, including structural concerns such as cost barriers and access to in-person healthcare services. It is critical to address these challenges to ensure successful implementation of new PrEP formulations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. A leap forward in assessing host-directed therapies for tuberculosis
- Author
-
Ignatius, Elisa H and Dooley, Kelly E
- Published
- 2021
- Full Text
- View/download PDF
16. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis.
- Author
-
Ignatius, Elisa H, Wang, Kunbo, Karaba, Andrew, Robinson, Matthew, Avery, Robin K, Blair, Paul, Chida, Natasha, Jain, Tania, Petty, Brent G, Siddiqui, Zishan, Melia, Michael T, Auwaerter, Paul G, Xu, Yanxun, and Garibaldi, Brian T
- Subjects
- *
COVID-19 treatment , *COVID-19 , *TOCILIZUMAB , *HOSPITAL patients , *COHORT analysis - Abstract
Background There is currently no single treatment that mitigates all harms caused by severe acute respiratory syndrome coronavirus 2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as an adjunctive immune-modulating therapy. Methods This was an observational retrospective study of hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19). The intervention group comprised patients who received tocilizumab; the comparator arm was drawn from patients who did not receive tocilizumab. The primary outcome was all-cause mortality censored at 28 days; secondary outcomes were all-cause mortality at discharge, time to clinical improvement, and rates of secondary infections. Marginal structural Cox models via inverse probability treatment weights were applied to estimate the effect of tocilizumab. A time-dependent propensity score–matching method was used to generate a 1:1 match for tocilizumab recipients; infectious diseases experts then manually reviewed these matched charts to identify secondary infections. Results This analysis included 90 tocilizumab recipients and 1669 controls. Under the marginal structural Cox model, tocilizumab was associated with a 62% reduced hazard of death (adjusted hazard ratio [aHR], 0.38; 95% CI, 0.21 to 0.70) and no change in time to clinical improvement (aHR, 1.13; 95% CI, 0.68 to 1.87). The 1:1 matched data set also showed a lower mortality rate (27.8% vs 34.4%) and reduced hazards of death (aHR, 0.47; 95% CI, 0.25 to 0.88). Elevated inflammatory markers were associated with reduced hazards of death among tocilizumab recipients compared with controls. Secondary infection rates were similar between the 2 groups. Conclusions Tocilizumab may provide benefit in a subgroup of patients hospitalized with COVID-19 who have elevated biomarkers of hyperinflammation, without increasing the risk of secondary infection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
- Author
-
Dooley, Kelly E., Sachiko Miyahara, von Groote-Bidlingmaier, Florian, Xin Sun, Hafner, Richard, Rosenkranz, Susan L., Ignatius, Elisa H., Nuermberger, Eric L., Moran, Laura, Donahue, Kathleen, Swindells, Susan, Vanker, Naadira, Diacon, Andreas H., Miyahara, Sachiko, Sun, Xin, and A5312 Study Team
- Subjects
MULTIDRUG-resistant tuberculosis ,ISONIAZID ,CLINICAL trials ,BACTERICIDES - Abstract
Rationale: High-dose isoniazid is recommended in short-course regimens for multidrug-resistant tuberculosis (TB). The optimal dose of isoniazid and its individual contribution to efficacy against TB strains with inhA or katG mutations are unknown.Objectives: To define the optimal dose of isoniazid for patients with isoniazid-resistant TB mediated by inhA mutations.Methods: AIDS Clinical Trials Group A5312 is a phase 2A, open-label trial in which individuals with smear-positive pulmonary TB with isoniazid resistance mediated by an inhA mutation were randomized to receive isoniazid 5, 10, or 15 mg/kg daily for 7 days (inhA group), and control subjects with drug-sensitive TB received the standard dose (5 mg/kg/d). Overnight sputum cultures were collected daily. The 7-day early bactericidal activity (EBA) of isoniazid was estimated as the average daily change in log10 cfu on solid media (EBAcfu0-7) or as time to positivity (TTP) in liquid media in hours (EBATTP0-7) using nonlinear mixed-effects models.Measurements and Main Results: Fifty-nine participants (88% with cavitary disease, 20% HIV-positive, 16 with isoniazid-sensitive TB, and 43 with isoniazid-monoresistant or multidrug-resistant TB) were enrolled at one site in South Africa. The mean EBAcfu0-7 at doses of 5, 10, and 15 mg/kg in the inhA group was 0.07, 0.17, and 0.22 log10 cfu/ml/d, respectively, and 0.16 log10 cfu/ml/d in control subjects. EBATTP0-7 patterns were similar. There were no drug-related grade ≥3 adverse events.Conclusions: Isoniazid 10-15 mg/kg daily had activity against TB strains with inhA mutations similar to that of 5 mg/kg against drug-sensitive strains. The activity of high-dose isoniazid against strains with katG mutations will be explored next.Clinical trial registered with www.clinicaltrials.gov (NCT01936831). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Reply to Decroo : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
- Author
-
Dooley, Kelly E., Miyahara, Sachiko, von Groote-Bidlingmaier, Florian, Xin Sun, Hafner, Richard, Rosenkranz, Susan L., Ignatius, Elisa H., Nuermberger, Eric L., Moran, Laura, Donahue, Kathleen, Swindells, Susan, Vanker, Naadira, Sun, Xin, and Diacon, Andreas H
- Subjects
RIFAMPIN ,TUBERCULOSIS treatment - Published
- 2020
- Full Text
- View/download PDF
19. Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease.
- Author
-
Ignatius EH, Rimal B, Panthi CM, Belz DC, Lippincott CK, Deck DH, Serio AW, and Lamichhane G
- Subjects
- Animals, Mice, Female, Treatment Outcome, Microbial Sensitivity Tests, Lung Diseases drug therapy, Lung Diseases microbiology, Administration, Oral, Lung microbiology, Clofazimine administration & dosage, Clofazimine therapeutic use, Linezolid administration & dosage, Linezolid therapeutic use, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Amikacin administration & dosage, Amikacin therapeutic use, Disease Models, Animal, Tetracyclines administration & dosage, Tetracyclines therapeutic use, Tetracyclines pharmacology, Mycobacterium abscessus drug effects, Drug Therapy, Combination, Imipenem administration & dosage, Imipenem therapeutic use, Imipenem pharmacology, Mycobacterium Infections, Nontuberculous drug therapy, Mycobacterium Infections, Nontuberculous microbiology
- Abstract
Treatment outcomes for Mycobacteroides abscessus ( Mab , also known as Mycobacterium abscessus ) disease are still unsatisfactory, mainly due to issues with drug toxicity, tolerability, and efficacy. Treating Mab disease is challenging due to its high baseline antibiotic resistance, initial requirement for intravenous therapy, and poor medication tolerance. Omadacycline, a new tetracycline, is active against Mab . Since any new antibiotic effective against Mab is expected to be used in combination with other antibiotics, we evaluated the efficacy of two triple-drug combinations comprising omadacycline, omadacycline + amikacin + imipenem, and omadacycline + clofazimine + linezolid against two contemporary Mab clinical isolates in a mouse model of Mab lung disease. Antibiotic administration was initiated 1-week post-infection and was given daily, with Mab burden in the lungs at treatment completion serving as the endpoint. Omadacycline alone moderately reduced Mab levels and maintained better health in mice compared to untreated ones, which typically suffered from the infection. The omadacycline + clofazimine + linezolid combination showed immediate bactericidal activity and enhanced efficacy over 6 weeks, particularly against the more resistant strain (M9507). However, the clofazimine + linezolid combination lacked early bactericidal activity. When combined with amikacin and imipenem, omadacycline did not improve the regimen's effectiveness over 4 weeks of treatment. Our study showed that omadacycline + clofazimine + linezolid exhibited significant bactericidal activity over an extended treatment duration. However, adding omadacycline to amikacin and imipenem did not improve regimen effectiveness against the evaluated clinical isolates within 4 weeks. Further research in Mab disease patients is needed to determine the most effective omadacycline-containing regimen.IMPORTANCE Mycobacteroides abscessus is a common environmental bacterium that causes infections in people with compromised lung function, including those with bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, and weakened immune systems, especially among older individuals. Treating M. abscessus disease is challenging due to the limited effectiveness and toxicity of current antibiotics, which often require prolonged use. Omadacycline, a new antibiotic, shows promise against M. abscessus . Using a mouse model that mimics M. abscessus disease in humans, we studied the effectiveness of including omadacycline with recommended antibiotics. Adding omadacycline to clofazimine and linezolid significantly improved treatment outcomes, rapidly clearing the bacteria from the lungs and maintaining effectiveness throughout. This oral combination is convenient for patients. However, adding omadacycline to amikacin and imipenem did not improve treatment effectiveness within 4 weeks. Further study with M. abscessus patients is necessary to optimize omadacycline-based treatment strategies for this disease., Competing Interests: Daniel H. Deck and Alisa W. Serio are employees of Paratek Pharmaceuticals, Inc. All authors vouch for the integrity, completeness, and accuracy of the data and analyses and assume responsibility for the fidelity of the study.
- Published
- 2024
- Full Text
- View/download PDF
20. Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.
- Author
-
Ignatius EH, Abdelwahab MT, Hendricks B, Gupte N, Narunsky K, Wiesner L, Barnes G, Dawson R, Dooley KE, and Denti P
- Subjects
- Antitubercular Agents therapeutic use, Humans, Pyrazinamide therapeutic use, Nitroimidazoles therapeutic use, Rifamycins
- Abstract
Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid was recently approved for extensively drug-resistant tuberculosis in combination with bedaquiline and linezolid. Pretomanid may also have benefit as a treatment-shortening agent for drug-sensitive tuberculosis. It is unclear how and whether it can be used together with rifamycins, which are key sterilizing first-line drugs. In this analysis, data were pooled from two studies: the Assessing Pretomanid for Tuberculosis (APT) trial, in which patients with drug-sensitive pulmonary TB received pretomanid, isoniazid, and pyrazinamide plus either rifampin or rifabutin versus standard of care under fed conditions, and the AIDS Clinical Trials Group 5306 (A5306) trial, a phase I study in healthy volunteers receiving pretomanid alone or in combination with rifampin under fasting conditions. In our population pharmacokinetic (PK) model, participants taking rifampin had 44.4 and 59.3% reductions in pretomanid AUC (area under the concentration-time curve) compared to those taking rifabutin or pretomanid alone (due to 80 or 146% faster clearance) in the APT and A5306 trials, respectively. Median maximum concentrations ( C
max values were 30.1 and 59.5 mg·h/liter, respectively. Though pretomanid exposure in APT was significantly reduced with rifampin, AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively. Though pretomanid exposure in APT was significantly reduced with rifampin, AUC0-24 values were similar to those associated with effective treatment in registrational trials, likely because APT participants were fed with dosing, enhancing pretomanid relative bioavailability and exposures. Pretomanid concentrations with rifabutin were high but in range with prior observations. While pretomanid exposures with rifampin are unlikely to impair efficacy, our data suggest that pretomanid should be taken with food if prescribed with rifampin. (This study has been registered at ClinicalTrials.gov under identifier NCT02256696.)., (Copyright © 2021 American Society for Microbiology.)- Published
- 2021
- Full Text
- View/download PDF
21. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis.
- Author
-
Ignatius EH, Wang K, Karaba A, Robinson M, Avery RK, Blair P, Chida N, Jain T, Petty BG, Siddiqui Z, Melia MT, Auwaerter PG, Xu Y, and Garibaldi BT
- Abstract
Background: There is currently no single treatment that mitigates all harms caused by severe acute respiratory syndrome coronavirus 2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as an adjunctive immune-modulating therapy., Methods: This was an observational retrospective study of hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19). The intervention group comprised patients who received tocilizumab; the comparator arm was drawn from patients who did not receive tocilizumab. The primary outcome was all-cause mortality censored at 28 days; secondary outcomes were all-cause mortality at discharge, time to clinical improvement, and rates of secondary infections. Marginal structural Cox models via inverse probability treatment weights were applied to estimate the effect of tocilizumab. A time-dependent propensity score-matching method was used to generate a 1:1 match for tocilizumab recipients; infectious diseases experts then manually reviewed these matched charts to identify secondary infections., Results: This analysis included 90 tocilizumab recipients and 1669 controls. Under the marginal structural Cox model, tocilizumab was associated with a 62% reduced hazard of death (adjusted hazard ratio [aHR], 0.38; 95% CI, 0.21 to 0.70) and no change in time to clinical improvement (aHR, 1.13; 95% CI, 0.68 to 1.87). The 1:1 matched data set also showed a lower mortality rate (27.8% vs 34.4%) and reduced hazards of death (aHR, 0.47; 95% CI, 0.25 to 0.88). Elevated inflammatory markers were associated with reduced hazards of death among tocilizumab recipients compared with controls. Secondary infection rates were similar between the 2 groups., Conclusions: Tocilizumab may provide benefit in a subgroup of patients hospitalized with COVID-19 who have elevated biomarkers of hyperinflammation, without increasing the risk of secondary infection., (© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2020
- Full Text
- View/download PDF
22. Reply to Decroo et al. : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
- Author
-
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, and Diacon AH
- Subjects
- Humans, Isoniazid, Pyrazinamide, Rifampin, Tuberculosis, Tuberculosis, Multidrug-Resistant
- Published
- 2020
- Full Text
- View/download PDF
23. New Drugs for the Treatment of Tuberculosis.
- Author
-
Ignatius EH and Dooley KE
- Subjects
- Antitubercular Agents pharmacology, Diarylquinolines pharmacology, Humans, Treatment Outcome, Antitubercular Agents therapeutic use, Diarylquinolines therapeutic use, Tuberculosis, Multidrug-Resistant drug therapy
- Abstract
Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The "third wave" of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.